Fozia Shaheen, Michael W O'Reilly, Wiebke Arlt, Karl-Heinz Storbeck, Simon C Afford, Mark Sherlock, Benson Jacob, Marie McIlroy, Clare Miller, Tara McDonnell, Jingwen Mao, Angus Hann, Yiyu Fan, Leanne Cussen, Angela E Taylor, Lina Schiffer, George Clarke, Amarah V Anthony
Journal: European journal of endocrinology 2025;193(3):340-347
PMID: 40795393
OBJECTIVE
Excess production of adrenal-derived 11-oxygenated androgens is observed in congenital adrenal hyperplasia, premature adrenarche, and polycystic ovary syndrome. 11-Ketotestosterone is equipotent to testosterone but does not decline with age. To date, the precise hepatic metabolism of 11-oxygenated androgens and subsequent urinary metabolite excretion have not been characterised.
DESIGN
We employed an integrated approach combining an in vivo oral androgen challenge with an ex vivo normothermic machine liver perfusion (NMLP) model to characterise human hepatic 11-oxygenated androgen metabolism.
METHODS
Women with polycystic ovary syndrome were randomised to receive 150 mg of either oral dehydroepiandrosterone or 11-ketoandrostenedione (11KA4) for 7 days (n = 10 for each), with collection of 24-hour urine samples for multi-steroid profiling by liquid chromatography-tandem mass spectrometry pre- and post-intervention. We employed human liver tissue explants (n = 3) alongside a whole human liver NMLP model (n = 3) to characterise ex vivo 11-oxygenated androgen metabolism.
RESULTS
In ex vivo studies, the main metabolites identified were 11β-hydroxyandrosterone and 11β-hydroxyetiocholanolone. In vivo priming of the 11-oxygenated pathway with oral 11KA4 resulted in significant increases of urinary 11β-hydroxyandrosterone, 11β-hydroxyetiocholanolone, and 11-ketoetiocholanolone, all known to overlap with glucocorticoid metabolism. In addition, we observed significant increases in the urinary excretion of 11-ketoandrosterone (11KAn).
CONCLUSIONS
Using in vivo and ex vivo approaches, we report the predominance of 11β-hydroxy metabolites, highlighting the pivotal role of hepatic 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) activity in 11-oxygenated androgen metabolism. We identify 11KAn as the only metabolite without overlap with glucocorticoid metabolism, underscoring its specificity and biomarker potential. NMLP represents a novel integrated model to study human hepatic steroid metabolism.
© The Author(s) 2025. Published by Oxford University Press on behalf of European Society of Endocrinology.
Full Text Sources:
Medical:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.